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ABSTRACT
NKp46 (CD335) is a surface receptor shared by both human and mouse natural killer (NK) cells and
innate lymphoid cells (ILCs) that transduces activating signals necessary to eliminate virus-infected cells
and tumors. Here, we describe a spontaneous point mutation of cysteine to arginine (C14R) in the signal
peptide of the NKp46 protein in congenic Ly5.1 mice and the newly generated NCRB6C14R strain.
Ly5.1C14R NK cells expressed similar levels of Ncr1 mRNA as C57BL/6, but showed impaired surface
NKp46 and reduced ability to control melanoma tumors in vivo. Expression of the mutant NKp46C14R in
293T cells showed that NKp46 protein trafficking to the cell surface was compromised. Although
Ly5.1C14R mice had normal number of NK cells, they showed an increased number of early maturation
stage NK cells. CD49a+ILC1s were also increased but these cells lacked the expression of TRAIL. ILC3s
that expressed NKp46 were not detectable and were not apparent when examined by T-bet expression.
Thus, the C14R mutation reveals that NKp46 is important for NK cell and ILC differentiation, maturation
and function.
Significance
Innate lymphoid cells (ILCs) play important roles in immune protection. Various subsets of ILCs express
the activating receptor NKp46 which is capable of recognizing pathogen derived and tumor ligands and
is necessary for immune protection. Here, we describe a spontaneous point mutation in the signal
peptide of the NKp46 protein in congenic Ly5.1 mice which are widely used for tracking cells in vivo. This
Ncr1 C14R mutation impairs NKp46 surface expression resulting in destabilization of Ncr1 and accumula-
tion of NKp46 in the endoplasmic reticulum. Loss of stable NKp46 expression impaired the maturation of
NKp46+ ILCs and altered the expression of TRAIL and T-bet in ILC1 and ILC3, respectively.
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Introduction
Natural killer (NK) cells are cytolytic and cytokine-producing
cells that contribute to eradicate pathogen-infected cells and
cancers thereby mediating frontline defense and
immunosurveillance.1,2 The capacity to mediate these functions
depends on the balance between inhibitory and activating sig-
nals. Activating receptors include the family of natural
CONTACT Gabrielle T. Belz belz@wehi.edu.au; Evelyn Ullrich Evelyn.Ullrich@kgu.de Walter and Eliza Hall Institute of Medical Research, Melbourne,
Victoria, 3052, Australia; Division of Stem Cell Transplantation and Immunology, Department for Children and Adolescents Medicine, Johann Wolfgang Goethe
University Hospital, Frankfurt am Main, Germany
F.F.A and S.T. contributed equally and G.T.B. and E.U. contributed equally.
Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/koni.
Supplemental data for this article can be accessed here.
ONCOIMMUNOLOGY
2018, VOL. 7, NO. 10, e1475875 (15 pages)
https://doi.org/10.1080/2162402X.2018.1475875
© 2018 Taylor & Francis Group, LLC
cytotoxicity receptors (NCRs) NKp46, NKp30 and NKp44.3,4
NKp46 is expressed by NK cells and group 1 and 3 innate
lymphoid cells (ILCs).5-7 NKp46 is encoded by Ncr1 and associ-
ates with the ITAM-containing CD3ζ or FcRγ polypeptides.
Several endogenous ligands of NKp46 have been described
including the complement factor P,8 the intracellular filamen-
tous cytoskeletal protein vimentin expressed on the surface of
Mycobacterium tuberculosis–infected monocytes,9 and several
viral proteins such as hemagglutinin and hemagglutinin neur-
aminidases of the influenza,10,11 Sendai,12 Newcastle disease,13
ectromelia and vaccinia viruses.14 NKp46 was also shown to
recognize PfEMP1 of Plasmodium falciparum,14 an unknown
ligand from Fusobacterium nucleatum,15 adhesins from
Candida glabrata.16 This wide expression supports that the
triggering of NKp46 is essential for effective immune responses.
Previous studies have shown that mutations of the Ncr1
gene can cause a reduction in the cell surface expression of the
NKp46 protein. Various strains of mice have been generated
that either lack Ncr1 or exhibit mutations that have been
chemically induced.12,17,18 These lines (Ncrgfp/gfp, Ncr1Noe/Noe
and Ncr1iCre/iCre) exhibit different phenotypes, possibly as a
consequence of their difference in NKp46 protein expression.
For example, Ncr1Noe/Noe and Ncr1iCre/iCre strains harbor mod-
est gene changes but preserve the protein while Ncr1gfp/gfp
mice,17 and Ncr1gfp/gfpKlrk1−/- double knockout mice which
have defects in both NKp46 and NKG2D expression,19 lack
exons 5–7 resulting in a complete disruption of the protein.
Narni-Mancinelli et al.18 first described the effect of the point
mutationW32R in a colony of C57BL/6J mice carrying N-ethyl-
N-nitrosourea (ENU)–induced mutations (called Noé mice).
These mice had normal numbers of NK cells but showed an
impaired expression of NKp46 on the cell surface. Moreover,
Noé mice displayed an increased expression of the zinc-finger
protein Helios which is involved in the regulation of lymphocyte
development. Noé NK cells were hyper responsive to various
stimuli in vitro and Noé mice were more resistant to infection
with mouse cytomegalovirus.18 Glasner et al.20 further charac-
terized the effect of the Noé mutation clarifying that the
NKp46W32R protein could reach the surface of NK cells, but in
a slow and unstable manner. This resulted in an accumulation of
NKp46 in the endoplasmic reticulum (ER) and limited transport
to the cell surface.20 Recently, studies of humanNK cells carrying
the same mutation NKp46W32R led to similar conclusions.21
Here we describe the analysis of two independent colonies of
congenic CD45.1+ (Ly5.1) mice that exhibited a spontaneous
single point mutation (C14R, designated Ly5.1C14R mice) in the
signal sequence of the Ncr1 gene. This mutation impaired
NKp46 surface expression in ILC subsets. The C14R mutation
did not alter the overall expression ofNcr1mRNA inmutant NK
cells but impaired the surface expression of NKp46 in ILCs and
was associated with alteration in ILC maturation. These results
were also confirmed by a newly generated NCRB6C14R strain.
Results
Ly5.1 congenic mouse strains exhibit a reduced surface
expression of NKp46
Ly5.1 (B6.SJL-Ptprca Pepcb/BoyJ) congenic mice expressing
CD45.1 on the surface of all lymphocytes are classically used
in combination with CD45.2-expressing C57BL/6 mice to
establish experimental systems in which donor and host
immune cells can be faithfully tracked both at steady-state
and during an immune challenge. However, during analyses
of these types of systems, it was noticed that Ly5.1+ mice
consistently exhibited very poor expression of the receptor
NKp46, a key phenotypic marker of NK cells22 and some
subsets of ILCs, in multiple tissues including peripheral
blood (Figure 1A), bone marrow, peripheral lymph nodes
and spleen (Figure 1B). This observation was made in two
mouse colonies completely independent of each other but
which were originally derived from the Jackson Laboratory
(Jax) imported in 2008 (University Hospital Erlangen) and
2010 (Walter and Eliza Hall Institute, WEHI) and maintained
as closed colonies. This was distinct from newly imported
mice (2012, University Hospital Erlangen; 2016, WEHI), also
from Jax, which exhibited NKp46 expression equivalent to the
C57BL/6 lines and F1 mice derived from the originally
imported Ly5.1 line (C57BL/6 × Ly5.1WEHI) (SI Appendix,
Figure S1A). These findings suggested that this alteration was
a recessive trait limited to specific colonies that may have
carried the mutation. While this mutation was tightly linked
to the Ptprca locus on chromosome 1, Ncr1 is found on
chromosome 7 indicating that the alteration was not within
Ptprca itself.
A single amino acid change in the Ncr1 gene abrogates
stable NKp46 surface expression
To understand the basis of this alteration, we used whole
exome sequencing to examine C57BL/6 Ly5.1 (WEHI) and
Ly5.1 (WEHI) from the mouse colonies in Melbourne,
Australia. Assuming a recessive pattern of inheritance, 1042
SNPs were identified that were homozygous in the affected
mice and heterozygous in the parental strain (SI Appendix,
Dataset S1). Of these, 670 SNPs were classified as low impact
mutations based on variant effector predictor analysis and as
such were excluded from further analysis. Based on the
observed phenotype, we initially concentrated on the candi-
date gene Ncr1. NKp46 is a 46 kDa type 1 transmembrane
glycoprotein characterized by a short intracellular tail, a single
transmembrane domain, and two extracellular Ig-like
domains. Sequence analysis identified a single homozygous
missense point mutation (T to C) in the signal peptide of Ncr1
in both strains of mice that exhibited low NKp46 protein
expression. We confirmed by Sanger sequencing that the
mutation was present in Ly5.1 WEHI (hereinafter referred
to as Ly5.1C14R ) mice and C57BL/6 × Ly5.1C14R but not
C57BL/6 mice and resulted in a single amino acid substitution
of cysteine to arginine (C14R; Figure 1C). In contrast, the
RNA level of Ncr1 did not significantly differ in NK cells from
C57BL/6, Ly5.1C14R, WT Ly5.1 and C57BL/6 × Ly5.1C14R mice
(Figure 1D). It should be noted that subsequent to identifica-
tion of this mutation in the established lines at each institu-
tion, new founders were imported to the WEHI (2016) to
establish a new ‘unmutated’ colony. Breedings were kept
entirely separate from the original colonies and progeny
from the new breedings were analysed. Of these, 39 of 88
mice tested exhibited a reduction in NKp46 expression by
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Figure 1. Ly5.1 congenic mouse strain exhibits reduced surface expression of NKp46 that alters the localization of the NKp46 protein. (A) Dot plot showing the
staining and frequency of NK1.1+NKp46+ cells in the peripheral blood lymphocytes of C57BL/6 and Ly5.1 mice. Data show representative plots gated on live
lymphocytes CD3− CD19− (n = 12 mice/genotype). (B) Dot plots showing the expression and frequency quantification of NK1.1+NKp46+ cells in the bone marrow
(BM), peripheral lymph node (pLN) and spleen of C57BL/6 and Ly5.1 mice. (A, B) Data show representative plots gated on live lymphocytes CD3−CD19− pooled from
two to five independent experiments (n = 4–12 mice/genotype/tissue). (C) Sanger sequencing analysis of the Ncr1 gene in C57BL/6, C57BL/6 × Ly5.1C14R and
Ly5.1C14R mice showing the position of the point mutation. (D) Relative levels of NKp46 transcripts in splenic NK cells of C57BL/6, Ly5.1C14R, WT Ly5.1 and C57BL/6 ×
Ly5.1C14R mice. Data show the mean ± SEM of 3–4 mice/genotype for one of three similar experiments. P values were calculated using an unpaired two-tailed
Student’s t test. (E) NKp46 localization in primary NK cells. Representative images of NK cells isolated from C57BL/6 and mutant Ly5.1C14R mice stained with anti-
NKp46 and anti-PDI primary antibodies, and AlexaFluor488-conjugated anti-goat and AlexaFluor546-conjugated anti-rabbit secondary antibodies (DAPI nuclear stain,
blue; anti-NKp46, red; PDI, green). Images were obtained using confocal scanning microscopy. Arrows indicate ER localization. Scale bar, 10 μm.
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flow cytometry.We further sequenced 29 mice from the new
colony; 9 were homozygous wild-type for the Ncr1 gene and
were used to reestablish the colony while the remainder were
heterozygous. Thus, it appears that the mutation has inadver-
tently been retained undetected long term in parent colonies.
The C14R Ncr1 mutation significantly impairs surface
NKp46 expression in 293T cells
As the discovery that a mutation in the leader sequence might
affect NKp46 cell surface expression or trafficking was unex-
pected, we sought to demonstrate that ectopic expression of the
NKp46C14R mutation itself was responsible for the alterations we
observed in the mutated Ly5.1 mice. To this end, 293T cells were
transfected with wild-type NKp46 or NKp46C14R cDNA, respec-
tively, and the expression of NKp46 was tracked by flow cyto-
metry. The surface expression of the NKp46C14R protein on
293T transfectants was significantly reduced compared with
wild-type NKp46 while the total cellular NKp46 expression was
at a comparable level (SI Appendix, Figure S1B and C), demon-
strating that the impaired surface expression of NKp46 in Ly5.1
mice in fact is due to the C14R mutation in the NKp46 signal
peptide. Analyses of freshly isolated naïve NK cells from wild-
type or Ly5.1C14R mice by confocal laser scanning microscopy
not only confirmed the reduced NKp46C14R surface localization,
but also revealed a spotted intracellular distribution of the
mutated NKp46C14R protein. Furthermore, the colocalization
of NKp46 with protein disulfide isomerase (PDI), an enzyme
in the endoplasmic reticulum, indicated an accumulation of
NKp46C14R in that cell compartment (Figure 1E and SI
Appendix, S1 D). Thus the C14R mutation in the signal peptide
of NKp46C14R resulted in disruption of NKp46 surface expres-
sion by failed trafficking within the cell.
Ly5.1C14R mice have normal numbers of total NK cells but
altered distribution of ILC subsets
We then interrogate if the C14R mutation might impact the
subsets of cells that normally express NKp46, i.e. NK cells, ILC1
and NCR+ ILC3s. Ly5.1C14R mice exhibited normal numbers of
NK1.1+CD3− NK cells in the majority of the tissues but these
numbers were significantly increased in the thymus compared
with control mice (Figure 2A and B). We then examined the
maturation status of NK cells by measuring the expression of
KLRG1 and CD11b in C57BL/6 and Ly5.1C14R NK cells
(Figure 2C and D). This revealed an increase in the immature
(Imm) NK cell subsets in the spleen but not in the liver of
Ly5.1C14R mice suggesting that steady-state signalling through
NKp46 may act to modulate early NK cell maturation. Similar
findings were observed when cells were analysed using CD27 and
CD11b (SI Appendix, Figure S2A and B) and in Noé NK cells (SI
Appendix, Figure S2C and D), a phenotype that was rescued by
the expression of human NKp46.
ILC1 were identified through the expression of the CD49a
integrin and of the absence of expression of the transcriptional
regulator Eomesodermin (Eomes) which is required for the devel-
opment of NK cells.23 This showed that similar to NK cells, ILC1
were also enriched in the thymus (Figure 2E) although the level of
expression of NKp46 in Ly5.1C14R mice was reduced by ~3-fold
for both populations across all tissues when compared to that
found in C57BL/6 mice and ~1.5-fold for C57BL/6 × Ly5.1C14R
mice (Figure 2F). A similar reduction in the expression of NKp46
was seen in NK cells and ILC1s from tissues analysed in mixed
bone marrow chimeras (SI Appendix, Figure S3). This effect was
not seen in mice that carried only the six base pair mutation that
encodes CD45.1 (CD45.1STEM) (SI Appendix, Figure S4) demon-
strating that the NKp46 expression defect in Ly5.1C14R mice is
intrinsic and not linked to Ly5.1 itself. In addition, hepatic ILC1
isolated fromLy5.1C14Rmice lacked expression of the TNF-related
apoptosis-inducing ligand, TRAIL (encoded by Tnfsf10) normally
characteristic of this population24 (Figure 2G, upper panels). Such
an effect was also seen in the Ncrgfp/gfp strain but not in Ly5.1STEM
mice (Figure 2G, lower panels and SI Appendix, S4 B and C).
To extend these analyses, we investigated how loss of
NKp46 influenced NCR+ and NCR− ILC3 subsets in the
lamina propria (LP) and intraepithelial (IE) compartments
of the small intestine (Figure 3). As expected, NCR+ ILC3
were not detectable in the Ly5.1C14R mice (Figure 3A and B)
while ILC2 were present in normal numbers (data not
shown). This was accompanied by an accumulation in both
the frequency and number of NCR− ILC3. However, the over-
all number of Rorγt+ ILC3 was similar suggesting that loss of
NKp46 did not adversely affect the development of total ILC3
at steady-state. Nevertheless, analyses of T-bet expression
revealed that it was upregulated within the NCR+ subset in
C57BL/6 mice as previously reported,25,26 while NCR− ILC3
from Ly5.1C14R mice did not show elevated levels of T-bet
when compared with the NCR− population in C57BL/6 mice
suggesting that NCR+ cells fail to develop (Figure 3C).
Ly5.1C14R mice have an altered sensitivity to stimuli in
vitro and fail to control tumors in vivo
To gain insight on the functional relevance of the C14R point
mutation, the degranulation capacity of total NK cells from
C57BL/6 and Ly5.1C14R mice was determined by staining for sur-
face CD107a expression following exposure to various stimuli in
vitro. As might be expected, NK cells from NKp46C14R mice were
significantly less responsive toNKp46 stimulation.WhenNK cells
were cross-linked through NK1.1, they showed a trend towards
increased degranulation which was not statistically significant on
the whole NK cell population (Figure 4A), but was statistically
significant when restricted to the immature NK cell subset (SI
Appendix, Figure S5), consistent with previous findings on Noé
mice.18 Regardless of this point, however, the in vitro anti-tumor
NK cell cytolytic capacity was intact in NK cells from Ly5.1C14R
mice (Figure 4B and SI Appendix, Figure S5). Combined, these
data suggest that NKp46C14R NK cells are functionally competent
and can induce cell lysis through multiple pathways but exhibit
defects in vitro when recognition requires engagement of NKp46.
These findings suggested that despite the alteration of NKp46
in Ly5.1C14R, NK cells should be competent to protect against in
vivo tumor challenge. To test this point, mice were inoculatedwith
B16F10 melanoma cells which are known to be controlled by NK
cells.27,28 While C57BL/6, C57BL/6 × Ly5.1C14R and Ly5.1 (Jax,
2017)mice were able to largely control tumor growth asmeasured
by the number of primary lung tumors 14 days after tumor
inoculation (Figure 4C and D), mice that expressed the
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Figure 2. Disruption of NK cell homeostasis and maturation of ILC1 and NK cells in Ly5.1C14R mice. (A) Dot plots showing the frequency of ILC1 and NK cells in the spleen. Data
show representative plots gated on live NK1.1+ lymphocytes excluding T and B cells in C57BL/6, Ly5.1C14R and C57BL/6 × Ly5.1C14R mice. (B) Total number of NK cells in spleen,
thymus, liver, small intestine lamina propria (LP) and within the intestinal intraepithelial compartment (IE). Data show the mean ± SEM pooled from three to six independent
experiments (n = 6–15 mice/genotype); thymus are pooled from three to five independent experiments (n = 6–12 mice/genotype). P values were calculated using an unpaired
two-tailed Student’s t test. (C) FACS plots showing the frequency of immature (Imm, KLRG1−CD11b−), mature 1 (M1, KLRG1−CD11b+) and mature 2 (M2, KLRG1+CD11b+) NK
cells in splenic NK1.1+CD3−CD19−NK cells. (D) Total number of Imm,M1 andM2 NK cells in the spleen and liver of C57BL/6, Ly5.1C14R and C57BL/6 × Ly5.1C14R mice showing the
mean ± SEM pooled from three to six independent experiments (n = 6–15 mice/genotype). P values were calculated using an unpaired two-tailed Student’s t test. (E) Total
number of ILC1s in spleen, thymus, liver, small intestine lamina propria (LP) and within the intestinal intraepithelial compartment (IE). Data show the mean ± SEM pooled from
three to six independent experiments (n = 6–15mice/genotype); thymus data are pooled from three to five independent experiments (n = 6–12mice/genotype). P values were
calculated using an unpaired two-tailed Student’s t test. (F) Histograms showing the mean fluorescence intensity of NKp46 in various tissues for both NK cells and ILC1 for wild-
type (black solid line), Ly5.1C14R (solid blue) and C57BL/6 × Ly5.1C14R (red solid line). CD3ε+ cells were used as a control for NKp46 expression (black dashed line). Data are
representative of tissues analyzed in (A–E). (G) Expression of TRAIL on NK1.1+CD49a+CD3−CD19− hepatic ILC1 in C57BL/6, Ly5.1C14R and C57BL/6 × Ly5.1C14R (results shown in the
upper panels) and in C57BL/6 controls compared to Ncr1gfp/gfp (results from experiment shown in the lower panels). Data show representative plots from three to five independent
experiments and indicate the the frequency of expression (n = 6–12 mice/genotype).
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NKp46C14R single point mutation developed significantly more
lung metastases, a condition that was accompanied by respiratory
distress. Thesemice also presentedmetastases in other organs such
as the kidney, liver and bonemarrow (SIAppendix, Figure S5D), a
phenotype which was similar to that observed inMcl-1fl/flNcr1iCre
mice in which NCR+ cells are conditionally ablated29 (Figure 4C
and D and SI Appendix, Figure S5D). Thus, although some func-
tionwas preserved in the presence of theC14Rmutation including
the ability of NK cells to localize to the lung itself (SI Appendix,
Figure S6), alteration of surface NKp46 in Ly5.1C14R mice strongly
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impaired the capacity of NK cells to control tumor development
and escape in vivo.
C14R mutation disrupts cellular pathways associated
with protein trafficking
To further dissect the molecular alterations that underpin the
changes that occur when the NKp46 expression is altered, we
analysed the transcriptome of naive C57BL/6 and Ly5.1C14R
NK1.1+ NK cells by RNA-seq analyses (Figure 5, SI Appendix,
Dataset S2). This revealed that there was a significant enrich-
ment in differentially regulated genes involved in intracellular
trafficking compartments including the endoplasmic reticu-
lum, endosome, ER to Golgi vesicle-mediated transport and
Golgi apparatus in Ly5.1C14R cells (Figure 5A–C). In addition,
alterations occurred in pathways associated with protein ubi-
quitination and transport together with enzymes associated
with processing of proteins (eg. GTPase, peptidase activity,
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protein kinase). Although changes to NKp46 trafficking may
have been expected, consistent with a similar alteration that
occurs in Noé mice,20,21 broader changes in protein trafficking
were not anticipated. Exome sequencing has uncovered that a
broad gene set is altered in the Ly5.1C14R strain that warrants
further investigation.
To determine how the NKp46C14Rmutationmight affect cells
responding to a tumor challenge, we isolated total NK cells from
the lungs of mice challenged with B16F10 tumor cells 7 days
earlier and subjected them to RNAseq (SI Appendix, Dataset S3).
Ninety-one genes were found to be differentially expressed
between C57BL/6 and Ly5.1C14R in NK cells in response to
melanoma (Figure 5D). Genes up regulated in C14R NK cells
were associated with the mitochondrion and cell differentiation,
while genes involved in protein processing in the endoplasmic
reticulum, transcriptional regulators and cellular organization
were downregulated (Figure 5D and E). However, genes such as
Cxcr3 and Cxcr4, both of which are essential for infiltration and
function of NK cells,30–32 and the transcriptional regulatorNab2
were upregulated in Ly5.1C14R. We observed that in Ly5.1C14R
mice, the number of NK cells found in the lung were enriched
~2.1 fold indicating that the failure of tumor control was not
driven by the inability to migrate to the lung.
Loss of NKp46 signaling is encoded by the point mutation
C14R in Ncr1
It was clear from the analyses above that many more genes than
would be anticipated are altered in Ly5.1C14R mice. Thus, we
could not be completely certain that the effects identified in
NKp46 expression in these mice are due solely to the C14R
mutation detected in the Ncr1 gene. To determine whether this
was indeed the case, we generated mice using the CRISPR/Cas9
technology33 that would carry only the C14R mutation on a
C57BL/6 background. These mice are designated as the
NCRB6C14R strain and were healthy, viable and bred normally
to produce homozygous animals. Analyses of NKp46 surface
expression in C57BL/6 and NCRB6C14R mice showed that the
C14R mutation alone abrogated NKp46 binding phenocopying
the Ly5.1C14R mice for this feature (Figure 6). Similarly, the
distribution of NK cells in NCRB6C14R mice were concordant
with the pattern observed in Ly5.1C14Rmice (Figure 6B–D) while
in both NCRB6C14R and Ly5.1C14R ILC1 were enriched in spleen
and liver in four to five week old mice (Figure 6E). We also
observed that NKp46+ ILC3 were reduced in NCRB6C14R similar
to that observed in Ly5.1C14R mice. Notably across all organs
examined, the surface expression of NKp46 was strongly
reduced in NK cells and ILC1 and in blood NK cells
(Figure 6F). This correlated with a strong reduction in TRAIL
expression when C57BL/6 mice expressed the C14R mutation
demonstrating that an alteration in NKp46 which affects the
stability of the expression at the surface of the cell is sufficient
to alter the induction of TRAIL in hepatic ILC1.
Discussion
Spontaneous mutations occur in eukaryotes at a rate of 0.1–
100 per genome per sexual generation. In mice, nearly 5,000
spontaneous and induced mouse mutant alleles with clinically
relevant phenotypes have been described in the Mouse
Genome Informatics database and only about one third of
these have characterized phenotypes.34 In many cases, how-
ever, identification of these sequence alterations has served as
a rich source of animal models for human genetic diseases.
Although the Ly5.1 (CD45.1) line should differ from its ‘wild-
type’ counterpart by just five amino acids within the extracellular
domain,35 it is now clear that the B6.SJL-Ptprca Pepcb/BoyJ
derived from Jax differs in many genes from the C57BL/6 line
spanning ~40Mb and ~300 genes.36 A single amino acid
accounts for the difference between the CD45.1 and CD45.2
congenic markers that define these two strains36 and this differ-
ence has formed the basis for their use in extensive tracking
experiments. These previously unappreciated alterations in the
genome have most likely impacted experimental interpretations.
We now add to this list the detection of a spontaneous mutation
in the Ncr1 gene that has affected multiple mouse colonies in
geographically distinct locations. This mutation may have arisen
independently, but seems most likely to have arisen from an
individual breeding founder from the Jax. As the C14Rmutation
of the Ncr1 gene remains undetected in heterozygous animals,
this mutation has inadvertently been retained undetected long
term in parent colonies. Using whole exome sequencing we
identified a spontaneous single autosomal recessive mutation
in the Ncr1 gene that significantly altered the expression of the
NKp46 surface protein by interfering with its export to the cell
surface. Subsequently, we generated C57BL/6 mice in which we
introduced the C14R mutation in the Ncr1 gene negating the
effect of other genes altered in the Ly5.1C14R strain. This directly
confirmed that the change in NKp46 expression was solely
driven by this mutation and will allow this specific mutation to
be investigated in detail in future studies.
The C14R mutation in the Ncr1 gene of the mutant
Ly5.1 lines occurred just proximal to the previously
reported W32R mutation in the signal peptide which can
typically affect the synthesis and/or secretion of a protein.-
18,21 We show that expression of Ncr1 mRNA was similar
in NK cells of both wild-type, Ly5.1C14R mouse strains
suggesting that the gene is effectively transcribed but that
alterations occur after this stage. The Noé strain also
showed poor cell surface expression of NKp46, and like
the NKp46C14R NK cells, displayed no change in mRNA
expression.18 This was supported by analysis of transduced
293T cells where intracellular NKp46C14R and NKp46
expression were similar, but cell surface expression was
strongly impaired in NKp46C14R. Genomic analyses
revealed disruption in intracellular trafficking although a
broader group of genes involved in transcriptional regula-
tion and protein processing in the ER, endosome, Golgi
apparatus and cellular organization were detected suggest-
ing other potential defects in this mouse line. Collectively,
however, our data suggest that in the mutants, NKp46
could be expressed on the cell surface but is unstable
posing the possibility that an altered signaling pathway
could be triggered by the constant internalization of
NKp46. It also implies that the stability and/or level of
NKp46 expression is important in signaling and prompts
further dissection of the molecular control of NKp46 that
appears to impact on ILC differentiation.
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Figure 6. Loss of NKp46 surface expression depends on the C14Rmutation in the Ncr1 gene. (A) Dot plots showing the frequency of ILC1 and NK cells in the spleen. Data show
representative plots gated on live NK1.1+ lymphocytes excluding T and B cells. (B) Total number of NK cells in spleen, thymus, liver, small intestine lamina propria (LP) and within
the intestinal intraepithelial compartment (IE). Data are pooled from two independent experiments and show the mean ± SEM (n = 4–6 mice/genotype). P values were
calculated using an unpaired two-tailed Student’s t test. (C) FACS plots showing the frequency of immature (Imm, KLRG1−CD11b−), mature 1 (M1, KLRG1−CD11b+) andmature 2
(M2, KLRG1+CD11b+) NK cells in splenic NK1.1+CD3−CD19− NK cells. (D) Total number of Imm, M1 and M2 NK cells in the spleen and liver of C57BL/6, Ly5.1C14R and NCRB6C14R
mice showing the mean ± SEM pooled from two experiments (n = 4–6 mice/genotype). P values were calculated using an unpaired two-tailed Student’s t test. (E) Total number
of ILC1s in spleen, thymus, liver, small intestine lamina propria (LP) and within the intestinal intraepithelial compartment (IE). Data show the mean ± SEM pooled from two
independent experiments (n = 4–6 mice/genotype). P values were calculated using an unpaired two-tailed Student’s t test. (F) Histograms showing the mean fluorescence
intensity of NKp46 in various tissues for both NK cells and ILC1 for wild-type (black solid line), Ly5.1C14R (solid blue) and NCRB6C14R (solid orange). CD3ε+ cells were used as a
control for NKp46 expression (black dashed line). Data are representative of tissues analyzed in (A-E). (G) Expression of TRAIL on NK1.1+CD49a+CD3−CD19− hepatic ILC1 in
C57BL/6, Ly5.1C14R and NCRB6C14R. Data show representative plots from two independent experiments and indicate the the frequency of expression (n = 4–6 mice/genotype).
e1475875-10 F. F. ALMEIDA ET AL.
In the Ly5.1C14R mice, we observed that NK cell develop-
ment in terms of cellularity was not impaired in the absence
of NKp46. Neverthless, we show that the differentiation of NK
cells and ILC1 were altered in both Ly5.1C14R and Noé mice.
NK cell subsets were skewed towards an accumulation of less
mature NK cells and NCR− ILC3s. The lack of NKp46
induced in Ncr1gfp/gfp mice has also recently been shown to
be associated with an impaired NK cell maturation in
response to mouse cytomegalovirus infection (MCMV).37
This was associated with changes in CXCR3-driven migration
of NK cells to the regional lymph nodes which can affect NK-
dendritic cell crosstalk necessary for priming MCMV-specific
CD4+ T cells.38 In our study, we found that in contrast to this
observation, Cxcr3 mRNA was upregulated, consistent with
the higher expression of CXCR3 on the less mature
CD27highM1 NK cells.39,40 Indeed, the number of NK cells
that localized in the lung in response to a B16F10 tumor cells
which are likely to express the ligand for NKp46 was not
reduced in Ly5.1C14R mice (SI Appendix, Figure S4) and the
cytolytic machinery was intact. Ncr1gfp/gfp mice appear to
exhibit slightly reduced IFN-γ responses to NK1.1 stimulation
in vitro and murine cytomegalovirus infection.19,37
Stimulation through the NKp46 receptor has been shown to
drive IFN-γ production. This NK cell-driven IFN-γ produc-
tion has recently been shown to induce the extracellular
matrix protein fibronectin 1 that could modulate tumor
formation.41 In contrast, diminished NKp46 appears to reg-
ulate phosphorylation of Dok-1 to influence IFN-γ produc-
tion and pathogen protection.42 In our in vitro analyses, a
reduction in IFN-γ was not observed in our mutant mice
although signaling directly through NKp46 was strongly
impaired. Thus, it appears that the complete loss of function
of the Ncr1 allele in Ncr1gfp/gfp mice differs from the disrup-
tion induced by the introduction of a point mutation in the
gene.
In addition to changes in NK cell differentiation, we observed
that diminished NKp46 expression caused alterations in other
ILCs. Although loss of NKp46 did not impair ILC1 numbers, we
show that the apoptosis-inducing ligand TRAIL, which can be
induced by TGF-β43 and through viral binding to NKp4644 was
lacking implying that NKp46 may play a role in regulating
TRAIL expression. NKp46 is also a key marker of one of the
three subsets of ILC3.18 In Ly5.1C14R mice, as expected NCR+
ILC3 were not detectable via NKp46 expression but we also did
not see enrichment of expression of T-bet which is normally
associated with induction of this subset,25,26 although ILC3
development itself was not affected implying that activation of
NKp46 is important for the transcriptional program of these
cells. This is supported by cell fate mapping experiments that
suggest that instability of NKp46 expression in ILC3s found in
the intestine reflects a major role of this receptor in tuning the
very dynamic environmental signals encountered that drive
ILC3 plasticity.45,46 Loss of Ncr1 has previously been shown
not to affect ILC3 development with Ncr1gfp/gfpRag2−/- mice
showing survival and clinical scores similar to control mice
when challenged with the enteric infection Citrobacter
rodentium.47 In this setting, NKp46 expression did not appear
to be essential for protection.
In summary, we have identified a commonly used mouse
line, the Ly5.1C14R, that carries a point mutation in the Ncr1
gene together with a large number of previously unknown
genes. The NCRB6C14R strain confirmed that the C14R Ncr1
mutation directly impaired the expression of surface NKp46
and alters differentiation of NK cells with increased accumu-
lation of immature stages. In addition, increased numbers of
ILC1 were found and these cells lacked TRAIL expression
while NCR+ ILC3 were not detected. Thus, although reduced
NKp46 expression did not disrupt either NK cell or ILC
development, it exerted an important impact on normal dif-
ferentiation, maturation and activation of these lineages.
Materials and methods
Mice
C57BL/6 and B6.SJL-Ptprca Pepcb/BoyJ (Ly5.1, originally
obtained from The Jackson Laboratory), C57BL/6 × B6.SJL-
PtprcaPepcb/BoyJ (C57BL/6 × Ly5.1 and B6.SJL-Ptprca Pepcb/
BoyJAX (imported 2016 and sequence verified) mice were
bred and maintained in-house at either the Walter and Eliza
Hall Institute of Medical Research (WEHI, Australia) or the
University Hospital Erlangen (Germany) under specific
pathogen-free conditions. Mice used in Frankfurt were
obtained from the Preclinical Experimental Animal Center
(PETZ) of the Friedrich Alexander University (FAU)
Erlangen-Nürnberg, Germany. Ncr1gfp/gfp, Noé mice and
Mcl1fl/flNcr1iCre mice have been previously described.17,18,29
CD45.1STEM mice36 were bred at the Massachusetts General
Hospital animal house (Boston). Male and female mice were
used between the ages of six to eight weeks and were age
matched unless otherwise stated. NCRB6C14R mice were used
at four to five weeks of age. Animal experiments followed the
National Health and Medical Research Council (NHMRC)
Code of Practice for the Care and Use of Animals for
Scientific Purposes guidelines and were approved by the
Animal Ethics Committee of the respective institutions.
Generation of NCRB6C14R mice
A new C57BL/6 mouse strain that carried the C14R mutation
in the Ncr1 gene (NCRB6C14R) was generated using CRISPR/
Cas9 as previously described.33 Briefly, one sgRNA of the
sequence TAGGGCTATGTCTGAGCCAG (10ng/μl), an
oligo donor of the sequence (gttgaatcaagagcagattggggggag
acagcatgccattaaccctgttttctagGGCTACGACTGAGCCAGCGT-
ATCAACACTGAAAAGGgtaagtccttccctcgaagtctcagggttgttctt-
atgggttca; 10ng/ul) and Cas9 mRNA (5ng/μl) were injected
into the cytosol of C57BL/6J zygotes to generate NCRB6C14R
point mutant mice.
Generation of mixed bone marrow chimeric mice
Mixed bone marrow chimeric mice were generated by recon-
stituting lethally irradiated (2 x 5.5Gy γ-irradiation, 137Cs
source) with a mixture (1:1 ratio; total 10 × 106 bone mar-
row cells/mouse) of Ly5.1C14R (CD45.1+/+) and C57BL/6
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× Ly5.1C14R (CD45.2+CD45.1+) bone marrow. Mice were
analysed 6–8 wk after reconstitution.
Isolation of intestinal intraepithelial and lamina propria
lymphocytes
Intestinal LPL were isolated from the intestine as previously
described.26,48
Cell isolation and flow cytometric analyses
Single cell suspensions were generated by forcing organs
through 70 μm sieves. Lymphocytes were isolated from liver
using a 33% isotonic Percoll (Amersham Pharmacia Biotech)
gradient centrifuged at 2000 rpm for 13 min at ambient
temperature. Single cell suspensions were blocked with PBS
containing 5 μg/ml anti-CD16/CD32 (2.4G2) and stained for
20–30 min on ice with fluorophore-conjugated antibodies,
unless stated otherwise. For analysis of surface molecules,
cells were stained with the following antibodies: anti-CD11b
(M1/70) (BD Biosciences, or Miltenyi), anti-CD3ε (145-2C11)
and anti-CD19 (1D3 and 6D5) (BioLegend), anti-KLRG1
(2F1), and anti-NK1.1 (PK136), anti-CD27 (LG.3A11), anti-
CD45.1 (A20), anti-CD45.2 (104), anti-CD49a (HMα1), anti-
B220 (RA3-6B2) (all from BD Biosciences), anti-NKp46
(29A1.4, eBioscience) and anti-CD49b (DX5, generated at
The Walter and Eliza Hall Institute hybridoma facility). Live
cells were identified by exclusion after staining with a fixable
viability dye (BD Biosciences or BioLegend). Intracellular
staining was performed using the Transcription Factor
Staining Buffer Set (eBioscience) and monoclonal antibodies
to EOMES (Dan11mag), GATA3 (TWAJ) (both from
eBioscience) and RORγt (Q31-378, BD Biosciences). For
IFN-γ detection, the monoclonal antibody XMG1.2 (BD
Pharmingen) was used. Flow cytometry was performed
using a LSRFortessa X-20 or Canto10C (BD Biosciences)
and FlowJo analysis software (Treestar).
Murine melanoma cells and pulmonary metastasis
B16F10 murine melanoma cells (mycoplasma negative) were
maintained in complete DMEM (Gibco) with 10% heat-inac-
tivated FCS, 2 mM of L-Glutamine, 100 U/mL penicillin, and
100 μg/mL streptomycin. 2.5 × 105 B16F10 cells were injected
into the tail vein of recipient mice. Fourteen days after injec-
tion, the lungs, liver, long bones and kidneys were harvested
and fixed in Bouin’s solution. B16F10 metastases were
counted using a dissecting microscope.49
Exome sequencing
To identify the genetic mutation responsible for the reduced
NKp46 expression in the Ly5.1C14R strain we performed
exome sequencing on two mice from this strain and the
C57BL/6 × Ly5.1C14R mice which expressed normal NKp46
protein levels (SI Appendix, Methods).
Sanger sequencing
To further confirm the Ncr1 mutation identified by exome
sequencing we performed Sanger sequencing on C57BL/6,
C57BL/6 × Ly5.1 and WEHI B6.SJL-Ptprca Pepcb/BoyJ mice
(SI Appendix, Methods).
Quantitative PCR
RNA was isolated from sorted NK cells and NKp46 expres-
sion was determined as described in SI Appendix, Methods.
Cloning
NKp46 cDNA were generated from RNA isolated from
purified NK cells of either C57BL/6 or Ly5.1C14R mice by
RT-PCR and cloned into the plasmid RSV.5neo-FlagHis
which provides C-terminal FLAG- and hexahistidine-tags.
Primers: NKp46 cDNA forward 5ʹ-GACTCCGCG
GGCCACCATGCTGCCAACACTCACTG-3ʹ, NKp46 cDNA
reverse 5ʹ-AGTCCTCGAG CAAGGCCCCAGGAGTTGC-3ʹ.
Transfection and flow cytometric analysis
293T cells were cultured in Dulbecco’s Modified Eagle’s
Medium and were transfected with the appropriate
RSV.5neo expression vectors containing NKp46 WT or
mutant cDNA with Flag- and hexahistidine-tag using
Applifect (AppliChem) (SI Appendix, Methods). Cells were
fixed and permeabilized with BD Cytofix/Cytoperm (BD
Biosciences) and subsequently stained with appropriate anti-
bodies for 20 min at 4°C. Antibodies used: FLAG-tag mAb
M2 (Sigma), anti-NKp46-PE mAb 29A1.4 (BioLegend), rat
IgG2a-PE isotype control RTK2758 (BioLegend), mouse
IgG1 isotype control N1G9, APC-conjugated F(ab)2-frag-
ments of goat anti-mouse IgG (Jackson ImmunoResearch).
Flow cytometry analysis was performed with a FACS Canto
II (BD Biosciences, Heidelberg, Germany) and data analyzed
using FlowJo (Tree Star, Ashland, OH).
Immunofluorescence staining
NK cells were isolated from the spleens of Ly5.1C14R and
C57BL/6 mice and centrifuged on lysine coated slides, then
fixed and stained with goat anti-mouse NKp46 antibody (R&D
Systems, AF2225, 1:100) and rabbit anti-mouse PDI (Cell
Signaling Technology, 3501S, 1:100) overnight, followed by
AlexaFluor488-conjugated donkey anti-goat IgG (H + L)
(ThermoFisher, A-11055, 1:250) and AlexFluor546-conjugated
donkey anti-rabbit IgG (H + L) (ThermoFisher, A-10040,
1:200). Images were analyzed using LAS AF (Leica
Application Suite – Advanced Fluorescence) software (SI
Appendix, Methods).
NK cell stimulation
Plates were coated overnight at 4°C with antibodies against
NK1.1 and NKp46 (10 μg/ml in PBS). 1.5 × 106 splenocytes
were cultured in 200μl of complete RPMI1640 media
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containing 10% heat-inactivated FCS, 2mM of L-Glutamine,
100 U/mL penicillin, and 100 μg/mL streptomycin in the pre-
sence of Golgi Stop and soluble CD107a for 4h at 37°C. The
YAC1 stimulation condition was obtained by adding 0.25 106
YAC1 cells to the well. Cells were subsequently stained and
analyzed by flow cytometry with an LSR Fortessa and data
analyzed using FlowJo (Tree Star, Ashland, OH).
Cytotoxicity assay
Europium release assay was used to assess the lytic capacity of
murine NK cells as described in SI Appendix, Methods.
RNA-seq analysis
RNA-seq analyses was performed on NK cells isolated from
the lungs of Ly5.1C14R and C57BL/6 mice seven days after
challenge with B16F10 melanoma tumor cells. These strains
were sourced from the sourced from the WEHI colonies.
Samples were sequenced on an Illumina NextSeq 500 gener-
ating 75 bp paired end reads. Two biological replicates of each
cell type were sequenced. RNA-seq Reads were aligned to the
GRCm38/mm10 build of the Mus musculus genome using the
Subread aligner.50 Only uniquely mapped reads were retained.
Genewise counts were obtained using featureCounts.51 Reads
overlapping exons in annotation build 38.1 of NCBI RefSeq
database were included. Genes were excluded from down-
stream analysis if they failed to achieve a CPM (counts per
million mapped reads) value of greater than 0.5 in at least two
libraries. Counts were converted to log2 counts per million,
quantile normalized and precision weighted with the voom
function of the limma package.52,53 A linear model was fitted
to each gene, and empirical Bayes moderated t-statistics were
used to assess differences in expression.54 A false discovery
rate cut-off of 0.15 was applied for calling differentially
expressed genes. Gene Ontology and gene enrichment ana-
lyses were performed using Metascape (http://metascape.org).
Raw data files for the RNA sequencing have been deposited in
the NCBI Gene Expression Omnibus under accession number
GSE113030.
Highlights
● A spontaneous mutation in the signal sequence of the
Ncr1 gene arose in the CD45.1 mouse strain
● Ncr1 C14R mutation impairs NKp46 surface expression
in NK cells, ILC1 and ILC3
● Destabilization of Ncr1 by the C14R mutation results in
accumulation of NKp46 in the endoplasmic reticulum
● Loss of stable NKp46 expression impairs the maturation
of NKp46+ ILCs and impairs tumor control
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